vorinostat has been researched along with Acute Lymphoid Leukemia in 8 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Children with acute lymphoblastic leukemia (ALL) diagnosed with resistant phenotypes, and those who relapse, have a dismal prognosis for cure." | 1.36 | Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. ( Barredo, JC; Leclerc, GJ; Leclerc, GM; Mian, AM; Mou, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshida, K | 1 |
| Fujita, A | 1 |
| Narazaki, H | 1 |
| Asano, T | 1 |
| Itoh, Y | 1 |
| Shirazi, PT | 1 |
| Eadie, LN | 1 |
| Heatley, SL | 1 |
| Page, EC | 1 |
| François, M | 1 |
| Hughes, TP | 1 |
| Yeung, D | 1 |
| White, DL | 1 |
| Rivera-Del Valle, N | 1 |
| Cheng, T | 1 |
| Irwin, ME | 1 |
| Donnella, H | 1 |
| Singh, MM | 1 |
| Chandra, J | 1 |
| Kuang, SQ | 1 |
| Fang, Z | 1 |
| Zweidler-McKay, PA | 1 |
| Yang, H | 1 |
| Wei, Y | 1 |
| Gonzalez-Cervantes, EA | 1 |
| Boumber, Y | 1 |
| Garcia-Manero, G | 1 |
| Burke, MJ | 1 |
| Lamba, JK | 1 |
| Pounds, S | 1 |
| Cao, X | 1 |
| Ghodke-Puranik, Y | 1 |
| Lindgren, BR | 1 |
| Weigel, BJ | 1 |
| Verneris, MR | 1 |
| Miller, JS | 1 |
| Leclerc, GJ | 1 |
| Mou, C | 1 |
| Leclerc, GM | 1 |
| Mian, AM | 1 |
| Barredo, JC | 1 |
| Okabe, S | 1 |
| Tauchi, T | 1 |
| Ohyashiki, K | 1 |
| Bachmann, PS | 1 |
| Piazza, RG | 1 |
| Janes, ME | 1 |
| Wong, NC | 1 |
| Davies, C | 1 |
| Mogavero, A | 1 |
| Bhadri, VA | 1 |
| Szymanska, B | 1 |
| Geninson, G | 1 |
| Magistroni, V | 1 |
| Cazzaniga, G | 1 |
| Biondi, A | 1 |
| Miranda-Saavedra, D | 1 |
| Göttgens, B | 1 |
| Saffery, R | 1 |
| Craig, JM | 1 |
| Marshall, GM | 1 |
| Gambacorti-Passerini, C | 1 |
| Pimanda, JE | 1 |
| Lock, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)[NCT00882206] | Phase 2 | 15 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Slow accrual) | ||
| A Phase I Dose Escalation of MK0457 in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia[NCT00500006] | Phase 1 | 3 participants (Actual) | Interventional | 2007-10-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
the percentage of methylated DNA (NCT00882206)
Timeframe: Day 0
| Intervention | percentage of DNA (Mean) |
|---|---|
| Decitabine / Vorinostat | 84.98 |
the percentage of methylated DNA (NCT00882206)
Timeframe: Day 33
| Intervention | percentage of DNA (Mean) |
|---|---|
| Decitabine / Vorinostat | 86.1 |
the percentage of methylated DNA (NCT00882206)
Timeframe: Day 5
| Intervention | percentage of DNA (Mean) |
|---|---|
| Decitabine / Vorinostat | 79.82 |
Response includes both complete remission (defined as <5% leukemic blasts in the bone marrow) and partial remission (defined as a greater than 35% reduction in the bone marrow leukemia blast percentage at day 33) (NCT00882206)
Timeframe: Day 33
| Intervention | participants (Number) |
|---|---|
| Decitabine / Vorinostat | 6 |
1 trial available for vorinostat and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Presch | 2014 |
7 other studies available for vorinostat and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
Topics: Acetylation; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; CpG Islands; Deoxycytidine | 2022 |
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia.
Topics: Animals; Janus Kinase Inhibitors; Mice; Oncogenes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; S | 2022 |
Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; DNA Fragmentation; Drug | 2018 |
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
Topics: Apoptosis; Azacitidine; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Blood Cells; Bo | 2013 |
Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; CCAAT-Binding Factor; Cell Line, Tumor; Exons; Gene | 2010 |
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
Topics: Adult; Antineoplastic Agents; Aurora Kinases; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Co | 2010 |
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; Bcl- | 2010 |